Next 10 |
China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024
Data will be instrumental in upcoming Phase 2 clinical trial of MLR-1023, Adhera’s novel Type 1 D iabetes drug candidate Company moving forward with application to transition from OTC to NASDAQ Baton Rouge, LA, Jan. 25, 2023 (GLOBE NEWSWIRE) ...
Adhera Therapeutics ( OTCQB:ATRX ) appointed company director since November 5, 2021 and with 35 years experience in research, development and commercialization in multinational pharmaceutical companies, Zahed Subhan as Board Chairman and Chief Executive Officer succeedi...
Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September 8, 2022, the Company’s Board of Directors (the “Board”) appointed Zahed...
Adhera Therapeutics ( OTCQB:ATRX ) said on Tuesday the company had entered a heads of terms agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin, a novel protein complex for targeted treatment of advanced cancers. Paclitaxel is a drug approved by the U...
Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has entered a Heads of Terms (also known as a Letter of Intent (“LOI”)) agreemen...
Adhera Therapeutics (OTCPK:ATRX +10.9%) is pleased to announce the appointment of Trond K. Waerness as Chairman of the Co.’s Board of Directors. Mr. Waerness has been serving as a Director at Adhera since April 2021, will be replacing Andrew Kucharchuk, who will remain CEO and Vic...
News, Short Squeeze, Breakout and More Instantly...
Adhera Therapeutics Inc Company Name:
ATRX Stock Symbol:
OTCMKTS Market:
China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...